Xanthigen^® is now Patent Protected!

Xanthigen® Issued U.S. Patent for the Application entitled “Composition for Treating Obesity”

MORRISTOWN, NJ – Polifenoles Naturales, S.L., better known as PoliNat, a Spanish company based in the Canary Islands, is  proud to announce the issuance today of its U.S. Patent #8,367,072 for Xanthigen®.  The United States Patent and Trademark Office issued the patent for the application entitled “COMPOSITION FOR TREATING OBESITY AND METHOD OF USING THE SAME.”  According to Miguel Jimenez del Rio, PhD, President & CEO of PoliNat, “It’s gratifying that Xanthigen has been recognized as being unique enough to earn a patent.  We’ve always felt that way and now Xanthigen has official recognition.”

Paul Flowerman, President of P.L. Thomas, Polinat’s global sales and marketing partner, congratulates Polinat on the successful outcome of this application, which was made over five years ago by the late Dr. Zakir Ramazanov.  Paul notes, “Dr. Ramazanov would be proud of this accomplishment but even more proud of the extraordinary advances Polinat has made under the leadership of Dr. Jimenez. Polinat is a cGMP-approved facility with state of the art extraction facilities and a growing global client base.”

Xanthigen® is a novel weight management supplement demonstrated to promote weight loss through synergistic effects of its components – brown seaweed extract standardized for fucoxanthin and pomegranate seed oil standardized for punicic acid.  This composition, now patented, improves metabolism (resting energy expenditure).  A peer-reviewed, double-blind, placebo-controlled clinical trial of 110 obese premenopausal women published in Diabetes Obesity & Metabolism demonstrated that subjects without and with nonalcoholic fatty liver disease taking 600 mg of Xanthigen® daily lost an average of 10.8 and 12.1 pounds, respectively, over a 16-week period.  Supplementation with Xanthigen® also resulted in significant body composition improvements, including liver and body fat, as well as improved blood lipids and liver enzymes.

“These benefits are logical given what we know about the putative mechanism of action for this ingredient,” says Dr. Jimenez del Rio.  “Fat cell differentiation and lipid accumulation is suppressed in response to Xanthigen® treatment of adipocytes in culture and fucoxanthin has been shown to upregulate the mitochondrial uncoupling protein 1 (UCP1) in white adipose tissue.”  Furthermore, Xanthigen® may tackle triglycerides via omega-3 fatty acids derived from the brown seaweed and through the pomegranate seed oil punicic acid that it contains.   Both of these components have demonstrated triglyceride-lowering properties.

Companies interested in the use of Xanthigen® in dietary supplements should contact PLT.